Hwail Pharmaceutical Co.Ltd (KQ:061250) — Stock Price
Hwail Pharmaceutical Co.Ltd (KQ:061250) is currently trading at ₩8870.00 KRW, up 1.72% today. Over the past 52 weeks, shares have ranged between ₩918.00 and ₩9040.00. This page tracks Hwail Pharmaceutical Co.Ltd's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Hwail Pharmaceutical Co.Ltd stock valuation.
Hwail Pharmaceutical Co.Ltd (061250) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hwail Pharmaceutical Co.Ltd's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hwail Pharmaceutical Co.Ltd Income Statement — Revenue, Profit & Earnings by Year
Hwail Pharmaceutical Co.Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩119.76 Billion | ₩122.54 Billion | ₩132.05 Billion | ₩106.99 Billion | ₩123.61 Billion |
| Cost of Revenue | ₩109.21 Billion | ₩111.02 Billion | ₩118.50 Billion | ₩96.43 Billion | ₩108.58 Billion |
| Gross Profit | ₩10.55 Billion | ₩11.52 Billion | ₩13.55 Billion | ₩10.56 Billion | ₩15.03 Billion |
| Research & Development | ₩711.43 Million | ₩670.02 Million | ₩631.79 Million | ₩733.44 Million | ₩741.65 Million |
| SG&A | ₩8.65 Billion | ₩8.40 Billion | ₩7.74 Billion | ₩5.16 Billion | ₩9.31 Billion |
| Total Operating Expenses | ₩119.00 Billion | ₩120.49 Billion | ₩127.03 Billion | ₩102.73 Billion | ₩119.03 Billion |
| Operating Income | ₩-924.32 Million | ₩-1.06 Billion | ₩-10.66 Billion | ₩3.15 Billion | ₩3.56 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | ₩265.06 Million | ₩18.94 Million | ₩11.42 Million | ₩115.81 Million | ₩137.48 Million |
| Income Before Tax | ₩8.17 Billion | ₩4.90 Billion | ₩-7.97 Billion | ₩4.44 Billion | ₩4.28 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩6.48 Billion | ₩3.86 Billion | ₩-6.33 Billion | ₩2.84 Billion | ₩2.81 Billion |
Hwail Pharmaceutical Co.Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hwail Pharmaceutical Co.Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩215.61 Billion | ₩186.00 Billion | ₩185.60 Billion | ₩194.15 Billion | ₩169.68 Billion |
| Total Current Assets | ₩133.79 Billion | ₩136.63 Billion | ₩138.07 Billion | ₩148.83 Billion | ₩106.39 Billion |
| Cash & Equivalents | ₩54.11 Billion | ₩66.82 Billion | ₩45.05 Billion | ₩39.12 Billion | ₩34.34 Billion |
| Short-term Investments | ₩18.15 Billion | ₩5.02 Billion | ₩30.30 Billion | ₩50.08 Billion | ₩3.35 Billion |
| Net Receivables | ₩27.28 Billion | ₩25.02 Billion | ₩28.56 Billion | ₩28.47 Billion | ₩29.77 Billion |
| Inventory | ₩29.22 Billion | ₩35.51 Billion | ₩29.11 Billion | ₩27.23 Billion | ₩34.85 Billion |
| Property, Plant & Equipment | ₩65.58 Billion | ₩32.93 Billion | ₩31.56 Billion | ₩30.63 Billion | ₩34.37 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩12.19 Billion | ₩11.55 Billion | ₩10.02 Billion | ₩12.49 Billion | ₩12.82 Billion |
| Total Current Liabilities | ₩11.71 Billion | ₩11.03 Billion | ₩7.94 Billion | ₩12.07 Billion | ₩12.36 Billion |
| Long-term Debt | — | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | ₩203.42 Billion | ₩174.45 Billion | ₩175.57 Billion | ₩181.66 Billion | ₩156.86 Billion |
| Retained Earnings | ₩83.85 Billion | ₩77.37 Billion | ₩73.51 Billion | ₩83.59 Billion | ₩80.74 Billion |
Hwail Pharmaceutical Co.Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hwail Pharmaceutical Co.Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩11.63 Billion | ₩7.02 Billion | ₩-233.56 Million | ₩20.09 Billion | ₩-201.69 Million |
| Capital Expenditures | ₩34.63 Billion | ₩2.10 Billion | ₩10.39 Billion | ₩2.47 Billion | ₩4.68 Billion |
| Free Cash Flow | ₩-23.00 Billion | ₩4.92 Billion | ₩-10.63 Billion | ₩17.62 Billion | ₩-4.88 Billion |
| Investing Cash Flow | ₩-49.56 Billion | ₩19.74 Billion | ₩9.84 Billion | ₩-36.78 Billion | ₩-26.33 Billion |
| Financing Cash Flow | ₩24.91 Billion | ₩-5.10 Billion | ₩-4.04 Billion | ₩21.13 Billion | ₩33.73 Billion |
| Dividends Paid | — | — | — | ₩0.00 | ₩2.05 Billion |
| Stock-Based Compensation | — | ₩7.53 Million | ₩24.30 Million | ₩40.00 Million | ₩44.34 Million |
| Depreciation | ₩1.27 Billion | ₩1.16 Billion | ₩1.87 Billion | ₩2.08 Billion | ₩2.07 Billion |
| Change in Cash | ₩-12.72 Billion | ₩21.78 Billion | ₩5.93 Billion | ₩4.78 Billion | ₩7.05 Billion |
Hwail Pharmaceutical Co.Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Hwail Pharmaceutical Co.Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 30, 2025 | 4.62 | — | — |
| Jun 30, 2025 | 6.80 | — | — |
| Apr 07, 2025 | 72.01 | — | — |
| Nov 14, 2024 | 1.07 | — | — |
| Aug 13, 2024 | -7.60 | — | — |
| May 10, 2024 | 18.00 | — | — |
| Nov 16, 2023 | 55.40 | — | — |
| Aug 16, 2023 | 11.61 | — | — |